ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 2:16 PM ET
ALXO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $171.46M
- EPS (TTM)
- -$1.13
- Dividend yield
- None
- 52-week range
- 1.05 – 2.66
- Day range
- 1.15 – 1.29
- Volume / Avg
- 690.14K / 1.04M
- Beta
- —
- Shares outstanding
- 138.28M
- Next earnings
- Nov 6, 2026
52-week range
ALXO stock today
On Oct 9, ALXO is trading at $1.24, adding $0.06 (5.08%), versus the S&P 500's 0.59% gain. At this level, ALXO sits near the bottom of its 52-week range of $1.05 to $2.66: 53.4% below the high, set on Feb 19, 2026 and 18.1% above the low. ALXO is up 4.4% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 40.1%.
ALX Oncology has posted a net loss over the last twelve months (EPS of -$1.13), so its P/E ratio is not meaningful. ALX Oncology's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About ALX Oncology
Company profileALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jason W. Lettmann
- Headquarters
- South San Francisco, CA
- Employees
- 48
- IPO year
- 2020
- Website
- alxoncology.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$4.60+270.97%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
- EPS estimate
- $-0.14
ALX Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NBPNovaBridge Biosciences ADR | 1.40 | +2.19% | $162.40M | vs ALXO |
| EMISEmmis Acquisition Corp. Class A | 10.27 | 0.00% | $162.02M | vs ALXO |
| ORGOOrganogenesis Holdings Inc. Class A | 1.30 | +1.17% | $166.63M | vs ALXO |
| NKTXNkarta Inc. | 2.23 | +0.23% | $159.37M | vs ALXO |
| ANTXAN2 Therapeutics Inc. | 4.49 | -4.06% | $169.44M | vs ALXO |
| MENSJyong Biotech Ltd. | 2.06 | -1.90% | $156.62M | vs ALXO |
| MSLESatellos Bioscience Inc. | 7.36 | +0.20% | $156.15M | vs ALXO |
| NERVMinerva Neurosciences Inc | 3.23 | +0.31% | $154.22M | vs ALXO |
Indexes, lists and sector
ALX Oncology stock FAQ
What is ALX Oncology's stock price today?
ALXO last traded at $1.24 as of Oct 9, 2:16 PM EDT, up 5.08% on the day. Prices are delayed at least 15 minutes.
When is ALX Oncology's next earnings date?
ALX Oncology is expected to report earnings on Friday, November 6, 2026. Analysts expect EPS of $-0.14.
Who is ALX Oncology's CEO?
Mr. Jason W. Lettmann is the chief executive officer of ALX Oncology Holdings Inc., which has about 48 employees.
What is the ALXO 52-week high?
The 52-week high for ALXO is $2.66 and the 52-week low is $1.05. The stock is currently 53.4% below its high.